For sometime on this thread we have been considering the possible second indication that we might peruse. The NASA/Space angle is certainly interesting but I struggle to see how it could be a commercial proposition. I was digging around in some of the latest academic research for Exenatide and I came across this.
GLP-1R Agonists Appear to Lower Glaucoma Risk in T2D Patients (uspharmacist.com)
and this
Exposure to glucagon-like peptide 1 receptor (GLP-1R) agonists reduces glaucoma risk (medrxiv.org)
It seems to me this is an excellent area for us to explore, it is a large market with little available treatment and no prophylactic options. It fits neatly within Alex Sinclair's area of clinical experience and expertise. Clearly at a board level Megan Baldwin (CEO/MD of Opthea) and Tom Duthy (Advisor with Ellex Laser/Nova Eye) and chairman Jason Loveridge (Genable) also have significant experience in related adjacent areas.
I am putting my money on an announcement in the area at some point next year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
8.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.237M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28352 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 8998 | 1 |
View Market Depth
| Last trade - 16.21pm 28/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable